Liver hypertrophy: A review of adaptive (adverse and non-adverse) changes—Conclusions from the 3rd International ESTP Expert Workshop

Hall, AP; Elcombe, CR; Foster, JR; Harada, T; Kaufmann, W; Knippel, A; Küttler, K; Malarkey, DE; Maronpot, RR; Nishikawa, A; Nolte, T; Schulte, A; Strauss, V; York, MJ

HERO ID

2718645

Reference Type

Journal Article

Subtype

Review

Year

2012

Language

English

PMID

22723046

HERO ID 2718645
Material Type Review
In Press No
Year 2012
Title Liver hypertrophy: A review of adaptive (adverse and non-adverse) changes—Conclusions from the 3rd International ESTP Expert Workshop
Authors Hall, AP; Elcombe, CR; Foster, JR; Harada, T; Kaufmann, W; Knippel, A; Küttler, K; Malarkey, DE; Maronpot, RR; Nishikawa, A; Nolte, T; Schulte, A; Strauss, V; York, MJ
Journal Toxicologic Pathology
Volume 40
Issue 7
Page Numbers 971-994
Abstract Preclinical toxicity studies have demonstrated that exposure of laboratory animals to liver enzyme inducers during preclinical safety assessment results in a signature of toxicological changes characterized by an increase in liver weight, hepatocellular hypertrophy, cell proliferation, and, frequently in long-term (life-time) studies, hepatocarcinogenesis. Recent advances over the last decade have revealed that for many xenobiotics, these changes may be induced through a common mechanism of action involving activation of the nuclear hormone receptors CAR, PXR, or PPARα. The generation of genetically engineered mice that express altered versions of these nuclear hormone receptors, together with other avenues of investigation, have now demonstrated that sensitivity to many of these effects is rodent-specific. These data are consistent with the available epidemiological and empirical human evidence and lend support to the scientific opinion that these changes have little relevance to man. The ESTP therefore convened an international panel of experts to debate the evidence in order to more clearly define for toxicologic pathologists what is considered adverse in the context of hepatocellular hypertrophy. The results of this workshop concluded that hepatomegaly as a consequence of hepatocellular hypertrophy without histologic or clinical pathology alterations indicative of liver toxicity was considered an adaptive and a non-adverse reaction. This conclusion should normally be reached by an integrative weight of evidence approach.
Doi 10.1177/0192623312448935
Pmid 22723046
Wosid WOS:000317078200001
Url https://doi.org/10.1177/0192623312448935
Is Certified Translation No
Dupe Override No
Is Public Yes
Language Text English
Keyword liver; hypertrophy; adverse; non-adverse; AhR; CAR; PXR; PPAR alpha; weight; fasting; clinical pathology; omics
Is Peer Review Yes